NON-SMALL CELL LUNG CANCER

This study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced non-small cell lung cancer. The goal was to see if the combination could slow cancer growth or improve survival. The trial was stopped early, so results are…

This early-phase study tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had certain genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This study tested two immunotherapy drugs, nivolumab and ipilimumab, for people with advanced non-small cell lung cancer that had spread. The goal was to see if this drug combination could control the cancer without needing chemotherapy. Only 5 people took part before the study w…

This early-phase study tested a new experimental drug, PF-08046032, alone or combined with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the …

This early-stage study tested a combination of an immunotherapy drug (atezolizumab) and a gene therapy (ADV/IL-12) in 13 people with advanced non-small cell lung cancer that had worsened after initial immunotherapy. The main goal was to check safety and see if the combination cou…

This study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with standard radiation before surgery for stage III non-small cell lung cancer. The goal was to see if this approach is safe and does not delay planned surgery. Only 9 people took part b…

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or with other cancer drugs to see if it is safe and tolerable. The study was terminated early, so results are limited.

This study tested a new drug (HBI-8000) combined with an existing immunotherapy (pembrolizumab) for people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and effective. Only 5 people took part before the study was stopped early.

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique mutations in their cancer. It was designed for people with advanced solid tumors like lung, pancreatic, or ovarian cancer who had not responded to s…

This early-stage study tested a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives growth in some lung cancers. The trial aimed to find a safe dose and see if the drug could shrink tumors in people with advanced non-small cell lung cancer that h…

This early-stage trial looked at the safety of giving radiation therapy either before or after an immunotherapy drug (pembrolizumab) in 13 people with advanced non-small cell lung cancer. The goal was to find the best sequence to control the disease. The study was terminated earl…

This early-phase study tested a new drug (PF-07826390) alone or with another drug (sasanlimab) in 10 people with advanced solid tumors like lung, colon, or kidney cancer. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested an experimental drug called telisotuzumab vedotin for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a specific gene change called MET amplification. The goal was to see if the drug could shrink tumors. The …

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, and it is not a cure—patients still need ongoing tre…

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This study tested a new drug called SAR444245 combined with other cancer treatments in 106 adults with advanced non-small cell lung cancer or pleural mesothelioma. The goal was to see if the combination shrank tumors. The trial was terminated early, so results are limited.

This early-phase trial tested a new drug, DCC-3084, alone or with other treatments, in people with advanced solid tumors linked to MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and check if tumors shrank. It was termin…

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in people with advanced solid tumors like breast, kidney, ovarian, head and neck, colorectal, lung cancer, or melanoma. The goal was to check safety and see if tumors shrank. The st…

This early-stage study tested a new drug called AUR106 in 21 adults with advanced cancers (lung, stomach, bladder, kidney, colon, or esophagus) that had come back or spread. The main goal was to find a safe dose and check how the drug moves through the body. The study was stopped…

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) in people with a type of lung cancer that had spread to the brain but wasn't causing symptoms. The goal was to see if the drugs could control the brain tumors and delay the need for radiatio…

This study looked at whether a structured exercise program could improve survival, function, and quality of life for people with advanced lung cancer. It included adults with stage III or metastatic non-small cell lung cancer who were already on maintenance immunotherapy. The stu…

This study tested whether adding the immunotherapy drug pembrolizumab to precise radiation therapy (SBRT) helps people with early-stage non-small cell lung cancer who cannot have surgery. About 448 adults took part. The trial was stopped early, so results are limited. The goal wa…

This study tested the drug capmatinib given before and after surgery for people with a certain type of non-small cell lung cancer that has a MET gene change. The goal was to see if the drug could shrink tumors before surgery and help prevent cancer from coming back. However, the …

This study tested a combination of two drugs, tarloxotinib and sotorasib, in adults with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their cancer had…

This early-stage trial tested a new drug, DCC-3116, alone or with other targeted therapies, in 91 adults with advanced solid tumors (like lung cancer) that have specific gene mutations. The study was terminated, meaning it stopped early, likely due to safety or lack of benefit. T…

This study tested an experimental drug called BT-001, injected directly into tumors, either alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (like melanoma, lung, or breast cancer). The goal was to see if it was safe and could shrink tumors. The…

This study tested whether the drug olaparib could help people with advanced non-small cell lung cancer (NSCLC) who responded to initial chemotherapy. Participants who had a good response to platinum-based chemo were randomly assigned to take either olaparib or a placebo daily to …

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer that no longer responds to hormone therapy, as well as other solid tumors like melanoma and lung cancer. The goal was to see if the drug could shrink tumors or slow dis…

This study tested a drug called tovorafenib in people aged 12 and older with advanced solid tumors that have specific genetic changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, but the results may help guide future treatments…

This early-stage study tested a new drug, PF-07265028, alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head & neck cancers. The goal was to find the safest dose and see if the drugs shrink tumors. The study was terminated early…

This study tested whether adding ociperlimab to tislelizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that hasn't been treated before. Participants had high levels of a protein called PD-L1 on their tumors. The trial was terminated…

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This study tested whether adding canakinumab to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer or slow tumor growth. The trial enrolled 673 adults who had not received prior treatment. The study was t…

This early-stage study tested a new drug, PF-07820435, alone or with another drug (sasanlimab), in 9 people with advanced solid tumors like lung, skin, and kidney cancers. The main goal was to check safety and find the right dose. The study was stopped early, so results are limit…

This study tested whether giving a higher dose of radiation directly to the main tumor could be safe for people with non-small cell lung cancer. Participants also received standard chemotherapy. The trial was stopped early after enrolling only 6 people, so results are limited.

This study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and…

This early-stage trial tested an experimental drug called MYTX-011 in people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a powerful chemotherapy directly to can…

This early-stage study tested an experimental drug called TAS3351 in 18 people with advanced non-small cell lung cancer that had a specific genetic change (EGFR C797S mutation). The goal was to see if the drug was safe and could shrink tumors. The study was stopped early, so resu…

This early-phase study tested a new treatment called ITIL-306 for people with advanced ovarian, lung, or kidney cancers that stopped responding to standard therapies. ITIL-306 uses a patient's own immune cells, modified to better recognize and attack tumors. The study was termina…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs shrank tumors and to study biomarkers. Only 5 people enrolled before the study was…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors (like lung or colon cancer) that have specific KRAS gene mutations. The main goals were to check safety and find the right dose. The study was…

This early-stage study tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had certain genetic changes (EGFR or HER2). The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, s…

This study tested a new treatment for advanced non-small cell lung cancer using a patient's own immune cells (TILs) combined with an immunotherapy drug. The goal was to see if the combination was safe and tolerable. However, the trial was terminated early and only enrolled 2 peop…

This study looked at whether combining the immunotherapy drug durvalumab with two different schedules of precise radiation could improve quality of life for people with advanced non-small cell lung cancer. Only one person enrolled before the study was stopped. The goal was to see…

This study tested a mobile app called ApricityCare for minority patients with non-small cell lung cancer who are receiving immunotherapy. The goal was to see if the app helps patients report side effects quickly, reduce treatment delays, and lower the need for hospital visits. Th…

This study looked at people with advanced non-small cell lung cancer who had a good response to immunotherapy (PD-1/PD-L1 blockers) for 6 to 12 months. The goal was to see if continuing or stopping treatment made a difference in keeping the cancer from growing. Only 8 people took…

This study tested whether monitoring daily step counts in people with locally advanced non-small cell lung cancer during chemoradiotherapy could help doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the…

This early-phase trial tested whether combining high-dose vitamin C with the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer before surgery. Only one person took part before the study was stopped. The main goal was to measure imm…